KRAS and colorectal carcinoma: We found that the mutation burden in both DCIS and CRC samples was highly correlated to pathways such as MYC regulation, oxidative phosphorylation, and KRAS signaling, which are known to play critical roles in tumorigenesis [26–28] (Fig. 2H).